Leonardo Taarea, DO
Sports Medicine · Birmingham, ALNPI 1912386848
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,040 of the $8,379 with a category attached, or 72.1%. Smith+Nephew accounts for 70.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $6,202 and has fallen 96.6% since, to $213 in 2025.
Across 77 payments — averaging $108.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$6K
- Amgen$725
- Pacira Therapeutics, Inc.$432
- Pacira Pharmaceuticals Incorporated$419
- Bioventus LLC$176
- Boehringer Ingelheim$125
- plus $576 from 11 others
What the payments were for
- Food & beverage$2,34028%
- Education$6,04072%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 1 | $5,928 |
| Amgen | 22 | $725 |
| Pacira Therapeutics, Inc. | 17 | $432 |
| Pacira Pharmaceuticals Incorporated | 8 | $419 |
| Bioventus LLC | 7 | $176 |
| Boehringer Ingelheim | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 1 | $119 |
| Johnson & Johnson | 4 | $61 |
| Exact Sciences | 3 | $59 |
| Radius Health, Inc. | 3 | $56 |
| Boston Scientific | 1 | $54 |
| Endo Pharmaceuticals Inc. | 3 | $49 |
| Lilly USA, LLC | 2 | $47 |
| UCB, Inc. | 1 | $45 |
| DJO, LLC | 1 | $39 |
| Vertex | 1 | $24 |
| Biogen | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,379 in reported general payments places this provider in the 65th percentile of 108 sports medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 67 | $1,229 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 13 | $1,067 |
| Meloxicam | 241 | $813 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $657 |
| Baclofen | 71 | $459 |
| Gabapentin | 44 | $283 |
| Levothyroxine Sodium | 33 | $251 |
| Omeprazole | 11 | $231 |
| Tamsulosin Hcl | 11 | $182 |
| Metformin Hcl | 11 | $177 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $176 |
| Cyclobenzaprine Hcl | 35 | $175 |
| Amlodipine Besylate | 14 | $77 |
| Glipizide | 11 | $67 |
| Losartan Potassium | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Birmingham
- Edward CainBirmingham$12.7M
- Mark RogersBirmingham$94K
- Amit MomayaBirmingham$77K
- Christoper GarrettBirmingham$58K
- Reaves CrabtreeBirmingham$47K
- David AdkisonBirmingham$46K
- Amir ShahienBirmingham$45K
- Christopher CarterBirmingham$42K
- Christian MerrillBirmingham$40K
- Thomas EvelyBirmingham$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.